- Find Meeting Information
- Access help and resources
- Get 24-hour guidance & information
800-934-9518
Sponsored
A landmark clinical trial published in The Lancet has found that semaglutide, the active ingredient in Ozempic and Wegovy, significantly reduced heavy drinking in people with alcohol addiction and obesity.
For anyone on a sobriety journey, or supporting a loved one through one, the research raises important questions about where medication fits alongside peer support, AA, and the lifestyle work of long-term recovery.
What the SEMALCO Trial Found
In a 26-week randomized, double-blind, placebo-controlled trial conducted at Psychiatric Centre Copenhagen, 108 participants with alcohol use disorder and comorbid obesity were assigned to receive either weekly semaglutide injections or placebo, alongside standardized cognitive behavioral therapy.
Semaglutide was associated with a reduction of 41.1 percentage points in heavy drinking days from baseline, compared to 26.4 percentage points for the placebo group, a statistically significant difference of 13.7 percentage points.
The drug also showed substantial effects on multiple secondary alcohol-related and somatic outcomes, and researchers concluded that semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder, supporting previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment approach.
The findings matter because, despite the scale of the alcohol addiction crisis, treatment options remain limited. Currently only three FDA-approved medications exist for alcohol use disorder: naltrexone, acamprosate, and disulfiram.
Semaglutide is not yet approved for this use, but the SEMALCO trial is one of the most rigorous studies to date supporting further investigation.
How Semaglutide May Affect Alcohol Cravings
Semaglutide is a GLP-1 receptor agonist, a class of drugs originally developed to manage blood sugar and weight. GLP-1 (glucagon-like peptide-1) is a hormone that regulates appetite and reward signaling in the brain.
Researchers believe this same mechanism may reduce the reward response to alcohol, making drinking feel less compelling.
Earlier work pointed in this direction. A 2025 study in JAMA Psychiatry found that once-weekly semaglutide reduced alcohol consumption in adults with alcohol use disorder in a separate randomized trial.
Swedish registry data published in JAMA Psychiatry also found that semaglutide was associated with the lowest risk of alcohol use disorder among several medications studied, with an adjusted hazard ratio of 0.64 compared to other treatments
None of this means Ozempic is a sobriety shortcut. The SEMALCO trial combined semaglutide with cognitive behavioral therapy, and the placebo group also showed meaningful reductions in heavy drinking, reflecting the real benefit of structured therapeutic support. Medication, in this context, amplifies the work people are already doing, not replace it.
How This Supports Long-Term Sobriety
For people in long-term recovery, this research is worth understanding without either dismissing it or overclaiming it. Alcohol addiction is a complex, chronic condition with biological, psychological, and social dimensions.
Medications that reduce craving can lower the daily cognitive load of staying sober, creating more mental space for the relational and spiritual work that programs like Alcoholics Anonymous are built on.
The 12 steps of AA are not incompatible with medication. Step One asks for honest acknowledgment of powerlessness over alcohol.
That honesty can include recognizing that the brain’s reward circuitry is genuinely disrupted, and that evidence-based medical support may be part of a complete recovery plan alongside meetings, sponsors, and service.
What the SEMALCO trial does not change: the importance of community. Participants in both the semaglutide and placebo groups received structured cognitive behavioral therapy throughout the trial. Human connection and accountability, in whatever form works best, remain central to lasting sobriety.
What to Talk to Your Doctor About
Semaglutide is not currently approved by the FDA for alcohol use disorder and is not available as a standard treatment option in the United States for this purpose.
The SEMALCO trial is a significant step toward potential approval, but clinical practice has not changed yet.
If you are curious about whether medications might support your sobriety, the three FDA-approved options, naltrexone (also available as a monthly injection called Vivitrol), acamprosate and disulfiram, are available now and worth discussing with a prescribing physician or addiction medicine specialist.
For many people, the combination of treatment with medication, behavioral therapy, and peer recovery programs like AA produces better outcomes than any single approach alone.
Staying Sober in the Meantime
Whatever the future holds for semaglutide, sobriety today is built on the same foundations it has always been: honest connection, consistent structure, and daily commitment.
Search sober.com’s directory of AA meetings to start receiving support. You can also call
800-948-8417
Sponsored
to speak with a treatment advisor.
Peter W.Y. Lee is a writer and historian of American history. His primary focus is on the Cold War era. His academic work examines the relationship between youth and popular culture and its impact on U.S. society during the twentieth century.
View ProfileEric Owens is a writer and editor with a bachelor degree in Philosophy, which has helped him with presenting complex information in a simple way that all audiences can understand. He specializes in the mental health and addiction recovery space. He’s also passionate about the environment and has extensive experience in creating content related to sustainability issues
View Profile